Savara Inc

Listed Company

SVRACIK 0001160308NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-118.84M

Total Assets

$253.44M

Equity

$203.13M

Shares Out

204.66M

Op. Cash Flow

$-101.00M

Business

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases, principally autoimmune pulmonary alveolar proteinosis (aPAP). Its main product candidate is MOLBREEVI (molgramostim), an inhaled recombinant human GM-CSF biologic delivered via the proprietary eFlow® Nebulizer System, and the company also offers diagnostic testing and expanded access support programs. Key business activities comprise clinical development, regulatory submissions, outsourced manufacturing and supply-chain management, and commercialization planning. Savara targets markets in the U.S., EU, UK, Japan and other international regions through clinical trial sites, regulatory filings, distributor partnerships, and physician-directed access programs.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	81	78	44	28	29
General and administrative	42	25	16	11	12
Depreciation and amortization	87,000	130,000	77,000	31,000	136,000
Total operating expenses	124	103	60	39	41
Loss from operations	−124	−103	−60	−39	−41
Interest income, net	4	6	4	−88,000	−2
Foreign currency exchange gain	310,000	51,000	76,000	−19,000	−99,000
Tax credit income	784,000	797,000	797,000	796,000	844,000
Loss on extinguishment of debt	−546,000	—	—	—	—
Total other income, net	5	7	5	689,000	−2
Net loss	−119	−96	−55	−38	−43
Basic (per share)	−0.53	−0.48	−0.33	−0.25	−0.32
Diluted (per share)	−0.53	−0.48	−0.33	−0.25	−0.32
Basic (shares)	222	198	165	153	134
Diluted (shares)	222	198	165	153	134
Gain (loss) on foreign currency translation	665,000	−523,000	133,000	−648,000	−887,000
Unrealized gain (loss) on short-term investments	−2,000	44,000	201,000	38,000	−50,000
Total comprehensive loss	−118	−96	−54	−39	−44

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	33	15	27	52	34
Short-term investments	203	181	136	74	127
Prepaid expenses and other current assets	6	6	4	3	4
Total current assets	242	202	166	129	165
Property and equipment, net	100,000	165,000	270,000	51,000	73,000
In-process R&D	12	10	11	11	11
Other non-current assets	84,000	242,000	387,000	116,000	251,000
Total assets	253	213	178	140	177
Accounts payable	6	5	4	1	1
Accrued expenses and other current liabilities	15	10	7	5	5
Total current liabilities	20	15	11	6	15
Long-term debt	30	27	26	26	17
Other long-term liabilities	0	87,000	247,000	54,000	117,000
Total liabilities	50	41	37	32	32
Commitments and contingencies (Note 10)	—	—	—	—	—
Common stock, $0.001 par value, 300,000,000 shares authorized as of December 31, 2025 and 2024; 204,567,283 and 172,423,223 shares issued and outstanding as of December 31, 2025 and 2024, respectively	204,000	173,000	140,000	116,000	116,000
Additional paid-in capital	811	661	534	447	445
Accumulated other comprehensive loss	−87,000	−750,000	−271,000	−605,000	5,000
Accumulated deficit	−608	−489	−393	−339	−301
Total stockholders equity	203	171	140	108	144
Total liabilities and stockholders' equity	253	213	178	140	177

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−119	−96	−55	−38	−43
Reduction in the carrying value of right-of-use assets	158,000	145,000	98,000	136,000	231,000
Amortization of debt issuance costs	453,000	271,000	271,000	334,000	552,000
Accretion on discount to short-term investments	−3	−5	−5	75,000	2
Stock-based compensation	14	10	4	2	3
Prepaid expenses and other current assets	97,000	−2	−456,000	1	−1
Non-current assets	98,000	11,000	−12,000	−57,000	—
Accounts payable and accrued expenses and other current liabilities	5	4	5	−319,000	−2
Net cash used in operating activities	−101	−89	−51	−35	−40
Purchase of property and equipment	−22,000	−25,000	−296,000	−9,000	−57,000
Purchase of available-for-sale securities, net	−205	−205	−194	−89	−161
Maturity of available-for-sale securities	182	165	137	131	83
Sale of available-for-sale securities, net	4	—	—	11	8
Net cash used in investing activities	−18	−40	−57	53	−69
Repayment of long-term debt	−27	—	—	−26	—
Proceeds from long-term debt, net	30	—	—	26	—
Issuance of common stock issued in underwritten offering, net of offering costs	140	94	—	—	—
Issuance of common stock upon exercise of prefunded warrants	2,000	7,000	—	—	—
Issuance of common stock upon at the market offerings, net	—	24	9	—	—
Proceeds from exercise of stock options	347,000	347,000	283,000	2,000	16,000
Reimbursement of commissions from the prior issuance of common stock upon at the market sales, net	—	46,000	—	—	—
Repurchase of shares for minimum tax withholdings	−5	−995,000	−1	−3,000	−78,000
Net cash provided by financing activities	138	118	83	87,000	121
Effect of exchange rate changes on cash and cash equivalents	−277,000	−5,000	−118,000	−90,000	−137,000
Increase (decrease) in cash and cash equivalents	18	−11	−26	18	11
Cash paid for interest	3	2	2	2	2

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro